Program

BREAK

FORUM

INVITED SYMPOSIUM

MEET THE PROFESSOR

ON-DEMAND ORAL

OTHER EVENT

PLENARY LECTURE

PRODUCT THEATER

SPONSORED SYMPOSIUM

SYMPOSIUM

Tuesday, 17 March, 2026

Time	Hall A1	Hall A2	Auditorium 10+11	Hall A3	Auditorium 15	Auditorium 12	Hall 180-181	On-Demand Virtual Gallery	Exhibition
07:00-20:00								ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:30-10:30			BALANCING THE AD’S EQUATION: TAU, PROTEOSTASIS, AND VULNERABLE NETWORKS	GENETIC RISK AND MOLECULAR MECHANISMS IN AD	PROTEOMICS, LIPIDOMICS & RELATED MECHANISMS	INTEGRATING SLEEP, EEG, AND DIGITAL BIOMARKERS IN NEURODEGENERATION	ADVANCING PRECISION BIOMARKERS ACROSS THE NEURODEGENERATIVE CONTINUUM
08:30-15:30		INVITED SYMPOSIUM (NO CME/CPD CREDIT) BY INVITATION ONLY
09:30-10:30	INDUSTRY SYMPOSIUM 01 (NO CME/CPD CREDIT)
10:30-11:00	COFFEE BREAK
11:00-13:00	INDUSTRY SYMPOSIUM 02 (NO CME/CPD CREDIT)		PREVENTION AND RESILIENCE IN DEMENTIA AND AGING	α-SYNUCLEINOPATHIES MECHANISMS, PATHOPHYSIOLOGY: MODELING OF DISEASE PROGRESSION	FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD	CHOLINERGIC MECHANISMS & TREATMENTS IN AD SPECTRUM	MOLECULAR DRIVERS OF NEURODEGENERATIVE DISORDERS
13:00-14:00	LUNCH BREAK
14:00-15:30			BIOMARKERS AND NETWORKS OF RESILIENCE TO AD	IMMUNE–METABOLIC NETWORKS DRIVING TAU PATHOLOGY AND NEURODEGENERATION		BIOMARKERS OF SYNAPTIC LOSS, TAU PROGRESSION, AND EARLY NETWORK DYSFUNCTION IN AD	GENOMIC AND MULTI-OMIC INSIGHTS IN AD, PD, AND RELATED DISORDERS
14:00-15:00	INDUSTRY SYMPOSIUM 03 (NO CME/CPD CREDIT)
14:00-15:45					THE APP PATHWAY: FROM HIDDEN FRAGMENTS TO THERAPEUTIC TARGETS IN AD
15:30-15:45	SHORT BREAK
15:45-16:45	PLENARY LECTURE 01, 02
16:45-17:00	SHORT BREAK
17:00-18:00	FIRESIDE DEBATE: INDUSTRY MEETS ACADEMIA: MOONSHOTS AND MILESTONES: IS THE FUTURE OF NEURODEGENERATION DRUG DISCOVERY IN STARTUPS, FOUNDATIONS, BIG PHARMA, OR ACADEMIA
18:05-18:50	ADPDTM CEREMONY AND AWARDS
18:57-20:00									WELCOME RECEPTION IN EXHIBITION

Wednesday, 18 March, 2026

Time	Hall A1	Hall A2	Auditorium 10+11	Hall A3	Auditorium 15	Auditorium 12	Hall 180-181	Exhibition/Product Theater	On-Demand Virtual Gallery	Exhibition
07:00-08:30									ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:00-08:30	PLENARY LECTURE 03: DON PRICE MEMORIAL LECTURE
08:30-08:40	BREAK
08:40-10:40	INDUSTRY SYMPOSIUM 04 (NO CME/CPD CREDIT)	MICROGLIA/ASTROGLIA FROM MECHANISMS TO POTENTIAL TREATMENTS	ALPHA-SYNUCLEIN, AGGREGATION, MISFOLDING, PATHOGENESIS AND TRANSLATIONAL ASPECTS	DECODING APOE: GENETICS, LIPIDS, AND DISEASE	TRANSLATIONAL DRUG DISCOVERY AND MODELS	WHITE MATTER SIGNATURES IN NEURODEGENERATION AND PROGNOSIS	MECHANISTIC BIOMARKERS DEFINING PROGRESSION IN AD, PD, AND LBD
10:40-11:10	EXHIBITION, POSTERS AND COFFEE BREAK
10:40-11:10								PRODUCT THEATER 01 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
11:10-12:50	INDUSTRY SYMPOSIUM 05 (NO CME/CPD CREDIT)
12:50-14:30	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
13:00-14:00							MEET THE PROFESSOR - TICKETED EVENT
13:00-13:30								PRODUCT THEATER 02 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
14:30-15:30	FORUM 01: BIOMARKERS TO BENEFIT: ACCELERATING TRANSLATION OF MULTI-MODAL BIOMARKERS INTO DISEASE-MODIFYING THERAPIES
14:30-16:30		DECODING THE AMYLOID–TAU AXIS IN AD	MITOCHONDRIAL PATHWAYS IN NEURODEGENERATION AND THERAPY	PREDICTING PD & LBD: BIOMARKERS AND BEYOND	REWIRING NEUROINFLAMMATION: MICROGLIA AND IMMUNE THERAPEUTICS	GENOMIC LANDSCAPES IN AD, PD, AND DEMENTIA	MODULATING NEUROINFLAMMATION, Α-SYNUCLEIN, LRRK2, AND DOPAMINERGIC REPAIR: EARLY HUMAN DATA
15:35-16:35	FORUM 02: BEYOND ONE SIZE FITS ALL: PRECISION DRUG DEVELOPMENT, AI METHODS, AND TRIAL DESIGN IN AD/PD
16:30-17:00	EXHIBITION, POSTERS AND COFFEE BREAK
16:30-17:00								PRODUCT THEATER 03 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
17:00-19:00	FLUID BIOMARKERS AND MULTIMODAL IMAGING: DIAGNOSIS, PROGNOSIS AND DISEASE PROGRESSION	GENETIC LANDSCAPES OF ALZHEIMER’S AND PARKINSON’S	FROM RISK TO RESILIENCE IN COGNITIVE DECLINE	INDUSTRY SYMPOSIUM 06 (NO CME/CPD CREDIT)	FUNCTIONAL AND STRUCTURAL IMAGING IN NEURODEGENERATION	CAA AND BBB DYSFUNCTION: DIAGNOSIS, RISK FACTORS AND CELLULAR CHANGES

Thursday, 19 March, 2026

Time	Hall A1	Hall A2	Auditorium 10+11	Hall A3	Auditorium 15	Auditorium 12	Hall 180-181	Exhibition/Product Theater	On-Demand Virtual Gallery	Exhibition
07:00-08:30									ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:00-08:30	PLENARY LECTURE 04
08:30-08:40	BREAK
08:40-10:40	INDUSTRY SYMPOSIUM 07 (NO CME/CPD CREDIT)	MECHANISMS AND THERAPEUTICS IN THE ALS–FTD SPECTRUM (SOD-1, TDP-43, C9ORF72 AND TMEM106B)	MECHANISTIC INSIGHTS INTO PD AND LBD PATHOLOGY	MECHANISTIC INSIGHTS INTO SEX DIFFERENCES IN NEURODEGENERATION	PERIPHERAL AND CENTRAL IMMUNITY ACROSS AD/PD	LIPIDS, APOE IN AD, PD & MS	MECHANISTIC MODIFIERS OF AD: APOE, IMMUNITY, AND NEURAL CIRCUITS
10:40-11:10	EXHIBITION, POSTERS AND COFFEE BREAK
10:40-11:10								PRODUCT THEATER 04 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
11:10-12:50	SYMPOSIUM
12:50-13:50	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
12:50-13:50							MEET THE PROFESSOR - TICKETED EVENT
13:00-13:30								PRODUCT THEATER 05 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
13:50-15:50	CHOLINERGIC PATHWAYS: FROM MECHANISMS TO TREATMENTS	INFLAMMATION, LIPIDS, AND GLIAL PATHWAYS IN DEMENTIA	GENETIC AND CELLULAR PATHWAYS - FROM LRRK2 TO LBD AND PD	AI AND DIGITAL TOOLS FOR AD/PD CARE	DECODING TAU AND ITS CELLULAR PARTNERS IN DISEASE	MULTIMODAL MECHANISMS DRIVING EARLY AD PROGRESSION
15:50-16:20	EXHIBITION, POSTERS AND COFFEE BREAK
15:50-16:20								PRODUCT THEATER 06 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
16:20-17:20	INDUSTRY SYMPOSIUM 09 (NO CME/CPD CREDIT)
16:20-18:20		ARIA AND CAA: MECHANISMS	LINKING PATHOLOGY AND BIOMARKERS ACROSS NEURODEGENERATIVE DISORDERS	PET AND MULTIMODAL IMAGING IN AD, PD, AND LBD	GUT–BRAIN AXIS IN AD AND PD	FLUID BIOMARKERS AND MULTIMODAL IMAGING	BIOMARKER PATHWAYS LINKING AMYLOID, TAU, AND NEURODEGENERATION
17:30-18:30	FORUM 03: REWIRING COGNITION: TARGETING CHOLINERGIC, SYNAPTIC, AND NETWORK-BASED MECHANISMS IN AD, PD, AND LBD

Friday, 20 March, 2026

Time	Hall A1	Hall A2	Auditorium 10+11	Hall A3	Auditorium 15	Auditorium 12	Hall 180-181	Exhibition/Product Theater	On-Demand Virtual Gallery	Exhibition
07:00-08:30									ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:00-08:30	PLENARY LECTURE 05
08:30-08:40	BREAK
08:40-10:40	INDUSTRY SYMPOSIUM 10 (NO CME/CPD CREDIT)	MOLECULAR NEUROINFLAMMATION PATHWAYS	SYNAPTIC DYSFUNCTION AND BIOMARKERS IN AD/PD	APOE 4 DISTICT SIGNATURE IN AD AND PD	PROTEIN AGGREGATES, NEUROGENESIS, AND TRANSLATIONAL OPPORTUNITIES	GENETICS, APOE AND LIPID PATHWAYS IN AD
10:40-11:10	EXHIBITION, POSTERS AND COFFEE BREAK
10:40-11:10								PRODUCT THEATER 07 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
11:10-12:50	INDUSTRY SYMPOSIUM 11 (NO CME/CPD CREDIT)
12:50-13:50	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
12:50-13:50							MEET THE PROFESSOR - TICKETED EVENT
13:00-13:30								PRODUCT THEATER 08 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
13:50-15:05				REIMAGINING PARKINSON CARE: THE POTENTIAL OF NOVEL THERAPIES AND REGENERATIVE MEDICINE
13:50-15:50	ABETA TARGETING THERAPIES IN AD: PROGRESS AND PERSPECTIVES	GENETIC INSIGHTS IN AD, PD AND PSYCHIATRIC DISORDERS	CEREBROVASCULAR CHANGES, CAA, BBB		FLUID BIOMARKERS AND IMAGING - LINKING MECHANISMS TO CARE	MECHANISMS AND PATHWAYS TO THERAPY IN AD, FTD, AND ALS
15:50-16:20	EXHIBITION, POSTERS AND COFFEE BREAK
15:50-16:20								PRODUCT THEATER 09 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
16:20-17:20	INDUSTRY SYMPOSIUM 13 (NO CME/CPD CREDIT)
16:20-18:20		TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS	PET, MULTIMODAL IMAGING AND BIOMARKERS IN CLINICAL USE ACROSS DEMENTIAS	ARIA AND CAA: BIOMARKERS	LYSOSOMAL STORAGE DISEASES AND ENDOLYSOSOMAL PROTEOSTASIS MECHANISMS	REAL-WORLD OUTCOMES AND MECHANISTIC INSIGHTS IN ANTI-AMYLOID TREATMENT	INTEGRATED BIOMARKERS FOR EARLY DETECTION AND MECHANISTIC STRATIFICATION
17:30-18:30	FORUM 04: TARGETS TO THERAPIES: TRANSLATIONAL R&D FOR Α-SYNUCLEIN, LRRK2, AND GBA PATHOLOGIES IN PD, LBD, AND MSA
18:30-18:40	SHORT BREAK
18:40-19:40	INDUSTRY SYMPOSIUM 14 (NO CME/CPD CREDIT)	COGNITIVELY HEALTHY CENTENARIANS: HOW DO THEY DO IT?	AD: GENETIC RISK AND BEYOND	AI, GENOTYPING, AND DIGITAL TOOLS IN NEURODEGENERATION	MODELING NEURODEGENERATIVE DISEASE IN PRIMATES	PSP IN FOCUS: MECHANISMS, MEASURES, AND MEDICINES

Saturday, 21 March, 2026

Time	Hall A1	Hall A2	Auditorium 10+11	Hall A3	Auditorium 15	Auditorium 12	Hall 180-181	Exhibition/Product Theater	On-Demand Virtual Gallery	Exhibition
07:00-08:30									ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)
08:00-08:30	PLENARY LECTURE 06
08:30-08:40	BREAK
08:40-10:40	ANTI-AMYLOID IMMUNOTHERAPY: MECHANISMS AND PRACTICE	TAU BIOLOGY AND THERAPEUTIC STRATEGIES	GLP-1 MECHANISMS AND THERAPEUTICS IN NEURODEGENERATION	RESTORING NEURAL RESILIENCE IN ALS AND ALZHEIMER’S DISEASE	NEXT-GENERATION BIOMARKERS ACROSS AD, PD, AND LBD	PATHWAYS TO NEURODEGENERATION: SYNAPSES, INFLAMMATION, AND PROTEINOPATHY
10:40-11:10	EXHIBITION, POSTERS AND COFFEE BREAK
10:40-11:10								PRODUCT THEATER 10 - SUPPORTED BY INDUSTRY (NO CME/CPD CREDIT)
11:10-13:10	ANTIBODIES & SHUTTLES FOR TARGETED BRAIN DELIVERY	PD AND LEWY BODY DISORDERS: FROM PREVENTION TO NOVEL THERAPIES	MICROGLIA AND NEUROIMMUNE TARGETS IN AD, FTD AND PD	BIOMARKER SIGNATURES IN PRECLINICAL AD AND NEURODEGENERATIVE DISEASES	TARGETING TAU: MECHANISMS AND THERAPIES
13:10-14:10	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS
13:10-14:10							MEET THE PROFESSOR - TICKETED EVENT
14:10-15:10	FORUM 05: IMMUNOTHERAPY 2.0: REDEFINING MICROGLIAL, TREM2, AND ADAPTIVE IMMUNE ENGAGEMENT IN AD AND PD
14:10-16:10		ADVANCES IN AD TREATMENT	EMERGING THERAPIES ACROSS AD, PD, LBD	TRANSLATIONAL TREATMENT STRATEGIES IN AD & FTD; NEW TARGETS	FLUID BIOMARKERS AND IMAGING IN AD, PD, LBD, HD	MOLECULAR SIGNATURES AND CONFORMATIONAL STATES IN AD AND LBD
15:20-16:20	FORUM 06: BEYOND AMYLOID AND TAU: EMERGING TARGETS AND MULTI-PATHWAY APPROACHES IN NEURODEGENERATION AND NEUROINFLAMMATION – PROMISE AND PITFALLS
16:20-17:00	EXHIBITION, POSTERS AND COFFEE BREAK
17:00-19:05		TAU, AMYLOID, AND SYNUCLEIN: MECHANISMS AND TREATMENTS	INTEGRATING IMAGING AND BIOMARKERS IN AD, PD, AND LBD	PROTECTIVE AND PATHOLOGICAL PATHWAYS IN COGNITIVE DECLINE	MOLECULAR MECHANISMS AND EMERGING THERAPIES IN PD, MSA AND LBD	TRACKING PD, GBA-PD AND MSA BIOMARKERS, MECHANISMS, AND PROGRESSION
17:00-17:45	PROF. DANNY MICHAELSON IN MEMORIAM PANEL DISCUSSION – “A LIFE-LONG PURSUIT OF ALZHEIMER’S THERAPEUTIC MODALITIES FOR APOE4 CARRIERS”
19:05-19:15	CLOSING SESSION